CRVS Insider Trading Activity and SEC Form 4 Filings
CRVS insider trading summary
Over the past 12 months, insiders at Corvus Pharmaceuticals, Inc. (CRVS) reported 3 open-market purchases worth $334K by 2 insiders and no sales on SEC Form 4. Net insider buying was $334K.
Latest CRVS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 11, 2026 | David Scott Moore | Insider | Buy | $250K (21,700 @ $11.53) |
| May 18, 2026 | Richard A Md Miller | President and CEO | Buy | $60K (5,000 @ $12.05) |
| May 18, 2026 | Richard A Md Miller | President and CEO | Buy | $23K (1,932 @ $12.01) |
| Jun 27, 2025 | Orbimed Advisors LLC | Director | Sell | $4.9M (1,176,332 @ $4.16) |
| Jun 27, 2025 | OrbiMed Capital GP V LLC | Director | Sell | $4.9M (1,176,332 @ $4.16) |
| Jun 27, 2025 | Peter A. Thompson | Director | Sell | $4.9M (1,176,332 @ $4.16) |
| May 6, 2024 | Richard A Md Miller | President and CEO | Buy | $1000K (577,634 @ $1.73) |
| May 6, 2024 | William Benton Jones | See Remarks | Buy | $35K (20,000 @ $1.73) |
| May 15, 2023 | Linda Grais | Insider | Buy | $25K (10,000 @ $2.45) |
| Dec 20, 2022 | William Benton Jones | See Remarks | Buy | $16K (20,000 @ $0.79) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.